What should I ask at a psoriasis appointment?
Prepare exact questions about skin goals, joint or nail concerns, treatment categories, monitoring and support.
Last updated
What supports the diagnosis, and what needs urgent care?
Ask what findings support psoriasis and what remains uncertain. Generalized pustular psoriasis and erythroderma require same-day specialist assessment. Seek urgent clinical help for a sudden widespread pustular eruption or extensive, rapidly spreading redness. Feeling acutely unwell increases the urgency, but do not wait for fever or other systemic symptoms. Evidence Evidence
What the sources support
Psoriasis assessment uses clinical history and examination. NICE identifies generalised pustular psoriasis and erythroderma as requiring immediate same-day specialist assessment.
What remains individual or uncertain
A photo, questionnaire or checklist cannot confirm psoriasis, identify a subtype or decide urgency for an individual. Other conditions can look similar.
Questions for your clinician
- What findings support psoriasis in my case? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Is the subtype clear, and what remains uncertain? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Which skin changes need same-day care? Saving keeps this on your device and needs JavaScript, which is off in this browser.
What do I want help with?
Start with the skin symptoms, locations and daily burdens that matter most to you. Bring prior treatment names and what made each workable or difficult. Evidence
What the sources support
A treatment discussion can compare multiple categories against goals, burden, medical context and access.
What remains individual or uncertain
A prepared list improves the conversation but does not identify the best treatment.
Questions for your clinician
- Which goals should we prioritize? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Which treatment categories fit those goals? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What from my prior care matters most to this decision? Saving keeps this on your device and needs JavaScript, which is off in this browser.
Do high-impact sites change the plan?
Tell the clinician about scalp, face, folds, genitals, palms, soles and nail involvement, and describe what those areas make difficult. A smaller affected area can still have a large physical, practical or emotional impact. Evidence
What the sources support
NICE assessment includes nails, high-impact or difficult-to-treat sites, symptoms, function, distress and wider life impact rather than relying on skin area alone.
What remains individual or uncertain
Naming a site does not determine severity, medicine strength, duration or the right treatment. Site-specific choices still require clinical assessment.
Questions for your clinician
- How do these sites affect how you assess severity? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Does function or distress change which categories we discuss? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What should I report if a sensitive site worsens? Saving keeps this on your device and needs JavaScript, which is off in this browser.
Should I mention joints, tendons and nails?
Yes. Mention joint pain or swelling, stiffness, tendon-area symptoms and nail changes so a clinician can decide whether another assessment is needed. Evidence
What the sources support
Psoriatic arthritis assessment depends on clinical evaluation, not one online symptom answer.
What remains individual or uncertain
These symptoms are not specific and this checklist cannot diagnose their cause.
Questions for your clinician
- Could these symptoms need a psoriatic arthritis assessment? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Who should I see about them? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Would they change our treatment discussion? Saving keeps this on your device and needs JavaScript, which is off in this browser.
Which safety context should I bring up?
Bring your medicine list and ask how infections, vaccines, pregnancy or pregnancy plans, other health conditions and prior treatment reactions change the options. Each medicine has product-specific limits and monitoring rather than one class-wide checklist. Evidence Evidence Evidence
What the sources support
Guidelines and current labels make medical history, monitoring and product-specific precautions part of systemic treatment decisions.
What remains individual or uncertain
This checklist cannot identify a contraindication, interpret a test, tell you to stop a medicine or replace the current label and clinician instructions.
Questions for your clinician
- How do pregnancy plans or other health conditions change the comparison? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Which infection, vaccine and medicine-interaction questions apply? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What monitoring belongs to the exact option we are discussing? Saving keeps this on your device and needs JavaScript, which is off in this browser.
How will access work?
Ask the plan which benefit and authorization process apply to the exact option, and which records are required. Also ask whether a designated supplier, pharmacy, or site of care must be used. The written plan and official decision control. Evidence Evidence
What the sources support
The exact option and written plan determine the benefit and authorization workflow.
What remains individual or uncertain
This page cannot predict approval, timing, personal cost, assistance eligibility or the rule used by a particular plan.
Questions for your clinician
- Which benefit and authorization process apply to this exact option? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Which records are required? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Must I use a designated supplier, pharmacy, or site of care? Saving keeps this on your device and needs JavaScript, which is off in this browser.
What should I know before leaving?
Ask what the plan requires, what monitoring or support goes with it, and what would prompt contact or review. Make sure you know where broader psoriasis education and help are available. Evidence Evidence
What the sources support
Different categories can carry different practical, monitoring and access requirements.
What remains individual or uncertain
Requirements vary by treatment and person; this page does not prescribe them.
Questions for your clinician
- What monitoring and support would this plan require? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What should prompt me to contact you? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Where can I find broader psoriasis education? Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a broad patient-facing map of topical treatment, phototherapy, oral systemic treatment and biologic treatment.
What it does not support
It does not rank categories or choose treatment for a particular person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute for Health and Care ExcellenceGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports psoriasis assessment across skin, nails, high-impact sites, life impact and joint concerns; same-day specialist assessment for generalised pustular psoriasis or erythroderma; and a treatment map that includes topical, phototherapy and systemic options.
What it does not support
It is UK guidance and does not diagnose a reader, create a US treatment sequence, determine personal urgency from a description, or establish current US labeling or coverage.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports bringing joint, tendon, swelling, stiffness and nail concerns to a clinician because diagnosis uses clinical assessment and may require further evaluation.
What it does not support
It is not an online screening result and cannot diagnose psoriatic arthritis from a checklist.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The guideline reports author relationships; it is not independent comparative proof for an individual choice.
What this source supports
Supports that methotrexate, apremilast, cyclosporine and acitretin are established systemic nonbiologic options considered in psoriasis care.
What it does not support
It does not select, rank or prescribe an option for an individual reader.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: FDA-approved prescribing information is authoritative for US labeling; it is product-specific regulator-approved labeling, not independent comparative clinical evidence.
What this source supports
Supports the current FDA-approved labeled plaque-psoriasis population, oral route, IL-23 receptor mechanism, and label precautions for Icotyde (icotrokinra).
What it does not support
The label states only “Revised: 3/2026”; it does not establish an exact revision day or the approval-action date. It also does not establish comparative superiority, personal suitability, insurance coverage, mature postmarketing evidence, or a class-wide conclusion. SteadySkin does not reproduce its regimen.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Centers for Medicare & Medicaid ServicesRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports distinguishing fully insured from self-funded employer coverage and identifying the plan or employer as the source of that answer.
What it does not support
It does not interpret a plan document, establish a benefit, or make a carrier medical policy controlling for a specific member.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The organization provides patient education, but its editorial and funding independence for this page was not independently reviewed. It is used only for patient-facing treatment-category context.
What this source supports
Supports patient-facing context that methotrexate, apremilast, deucravacitinib and acitretin are real oral treatment options discussed in psoriasis care.
What it does not support
It does not determine personal suitability, comparative benefit, coverage or a treatment sequence.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.